InspireMD to Present at JMP Securities Healthcare Conferenceon July 12th in New York
TEL AVIV, Israel, July 5, 2012 /PRNewswire/ –
InspireMD, Inc. (OTC BB: NSPR) (the “Company” or “InspireMD”), a medical device
company focusing on the development and commercialization of its proprietary stent
platform technology for use in patients with Acute Myocardial Infarctions, announced today
that Craig Shore, Chief Financial Officer, will present at the 7th Annual JMP Securities
Healthcare Conference on July 12th in New York City.
Presentation Details
- Date: Thursday, July 12, 2012
- Time: 3 PM
- Location: Chelsea Room, The Peninsula Hotel, 700 5th Avenue, New York, NY.
About the JMP Securities Healthcare Conference
The 7th Annual JMP Securities Healthcare Conference will take place at the Peninsula
Hotel in New York, July 12th – 13th. This institutional investor forum will feature more
than 100 publicly traded and privately held companies in the life sciences field.
JMP Securities is a full-service investment bank that provides equity research,
institutional brokerage and investment banking services to growth companies and their
investors. The firm specializes in four broad growth industries: Technology, Healthcare,
Financial Services and Real Estate. JMP’s research department covers primarily small and
mid-cap public companies
Attendance at this event is restricted to clients of JMP Securities. For full event
details and registration information, please click here:
http://www.jmpg.com/jmpsecurities/about/conferences.
About InspireMD, Inc.
InspireMD is a medical device company focusing on the development and
commercialization of its proprietary stent system technology, MGuard(TM). InspireMD
intends to pursue applications of this technology in coronary, carotid and peripheral
artery procedures. InspireMD’s common stock is listed on the OTC BB under the ticker
symbol “NSPR”.
About MGuard(TM) Coronary Stent
MGuard(TM) combines a coronary stent merged with an embolic protection specifically
designed for acute MI patients. The embolic protection is comprised of an ultra-thin
polymer micron net that is integrated with the stent. The MGuard(TM) is designed to
provide outstanding and lifelong embolic protection, without affecting deliverability.
MGuard(TM) is CE Mark approved. Mesh-based protection is now recommended for use in the
recent Guidelines of the Task force of Myocardial Revascularization of the European
Society of Cardiology (ESC).
MGuard(TM) is currently being investigated in the multi-center international MASTER
(MGuard(TM) for Acute ST Elevation Reperfusion) trial. This study has been designed to
evaluate the MGuard(TM) stent compared to commercially-approved BMS or DES products in
STEMI patients undergoing primary angioplasty. The trial is fully enrolled and preliminary
top line results are expected in the third quarter of 2012. Plans for a registration study
in the US are also at an advanced stage.
Forward-looking Statements:
This press release contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown risks and uncertainties,
many of which are beyond the Company’s control, and cannot be predicted or quantified and
consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without limitation,
risks and uncertainties associated with (i) market acceptance of our existing and new
products, (ii) negative clinical trial results or lengthy product delays in key markets,
(iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multi-national
companies, (v) product liability claims, (vi) our limited manufacturing capabilities and
reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (viii) our efforts to
successfully obtain and maintain intellectual property protection covering our products,
which may not be successful, (ix) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers
for certain product components, (xi) the fact that we will need to raise additional
capital to meet our business requirements in the future and that such capital raising may
be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in
multiple foreign jurisdictions, exposing us to foreign currency exchange rate
fluctuations, logistical and communications challenges, burdens and costs of compliance
with foreign laws and political and economic instability in each jurisdiction. More
detailed information about the Company and the risk factors that may affect the
realization of forward-looking statements is set forth in the Company’s filings with the
Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K and
its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s web site at http://www.sec.gov
[http://us.lrd.yahoo.com/SIG=117ej2487/EXP=1327079007/**http%3A//www.sec.gov ]. The Company
assumes no obligation to publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Investor Contact:
Michael Rice
Office Phone: +1-646-597-6979
Email: mrice@lifesciadvisors.com
Corporate Contact:
Jonina Ohayon
Marketing Director
Email: jonina@inspire-md.com
OTC BB: NSPR
http://www.inspire-md.com
[http://us.lrd.yahoo.com/SIG=11etph54c/EXP=1327079007/**http%3A//www.inspire-md.com ]
SOURCE InspireMD, Inc.
